Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbCellera Biologics Inc (ABCL) vs Duke Energy Corp (DUK) Price & Performance

AbCellera Biologics IncTrade
Duke Energy CorpTrade

Price performance (Past 24H)

Key statistics

AbCellera Biologics Inc vs Duke Energy Corp — how do they compare? AbCellera Biologics Inc trades at $9.26 (market cap $2.99B), while Duke Energy Corp trades at $123.08 (market cap $96.05B). The key difference: Duke Energy Corp is far larger — about 32.1× AbCellera Biologics Inc's market cap, and Duke Energy Corp pays a 3.52% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.

ABCLDUK
Market Cap
$2.99B$96.05B
Sector
HealthUtilities
52-Week High
$9.76$133.46
52-Week Low
$2.78$113.99
Enterprise Value
$2.58B$188.56B
Dividend Yield
3.52%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbCellera Biologics Inc

AbCellera Biologics (ABCL) surged 34.78% to $9.34, driven by positive Phase 2 trial results for its menopause drug ABCL635. Despite negative net income margins and cash burn, analyst consensus is strongly bullish with a $15.50 price target. The stock shows a bullish technical trend, with support at $8 and resistance at $10, though RSI levels indicate overbought conditions.

The outlook hinges on ABCL635's clinical progress and future revenue potential, but high valuation ratios and persistent losses pose significant risks. Investor sentiment is optimistic due to recent drug trial success, yet the company must demonstrate a path to profitability to justify current market enthusiasm.

Duke Energy Corp

Duke Energy (DUK) trades at $121.19, down 2.93% on the day, with a bearish technical signal. The company reported strong Q2 2026 earnings of $1.43 per share, beating estimates, and maintains solid fundamentals with a 15.78% net income margin. Recent news highlights operational challenges from storms affecting customers but also strategic initiatives like a $35 million equity units offering and data center growth opportunities.

The outlook is mixed; fundamentals are robust with consistent earnings beats and a healthy dividend, but technical weakness and high debt levels pose risks. Analyst consensus is a 'Hold' with a $136.17 price target, suggesting cautious optimism for long-term investors amid near-term volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbCellera Biologics Inc

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

Read more on ABCL

About Duke Energy Corp

Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure

Read more on DUK